|drug3416||Thrombomodulin Modified Thrombin Generation Assay (TGA-TM) Wiki||1.00|
|D004211||Disseminated Intravascular Coagulation NIH||0.45|
|D020141||Hemostatic Disorders NIH||0.26|
|D001778||Blood Coagulation Disorders NIH||0.26|
There is one clinical trial.
Inflammation and abnormalities in laboratory coagulation tests are inseparably tied. For example, coagulation abnormalities are nearly universal in septic patients. Coagulation disorders have also been reported in many patients with severe courses of Coronavirus disease 2019 (Covid-19). But it is difficult to assess these changes. Global coagulation tests have been shown to incorrectly assess in vivo coagulation in patients admitted to intensive care units. But other tests are available. Thrombin generation assay (TGA) is a laboratory test which allows the assessment of an individual's potential to generate thrombin. But also in conventional TGA the protein C system is hardly activated because of the absence of endothelial cells (containing natural thrombomodulin) in the plasma sample. Therefore the investigators add recombinant human thrombomodulin to a conventional TGA. Thereby the investigators hope to be able to depict in vivo coagulation more closely than global coagulation tests do.
Description: nM;Measure: ETP (AUC) without rhThrombomodulin (rhTM) Time: 6 months
Description: nM;Measure: ETP (AUC) with rhThrombomodulin (rhTM) Time: 6 months
Description: Ratio of endogenous thrombin potential (ETP) with rhTM to ETP without rhTMMeasure: ETP-ratio Time: 6 months
Description: Comparison of ETP-ratios from ICU patients and ETP-ratios from citrated plasma samples from healthy donorsMeasure: ETP-Normalisation Time: 6 months
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports